- Home
- ECX vs AKBA Comparison
ECX vs AKBA Comparison
Compare ECX & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ECX
- AKBA
- Stock Information
- Founded
- ECX 2017
- AKBA 2007
- Country
- ECX China
- AKBA United States
- Employees
- ECX N/A
- AKBA N/A
- Industry
- ECX EDP Services
- AKBA Biotechnology: Pharmaceutical Preparations
- Sector
- ECX Technology
- AKBA Health Care
- Exchange
- ECX Nasdaq
- AKBA Nasdaq
- Market Cap
- ECX 643.6M
- AKBA 729.1M
- IPO Year
- ECX N/A
- AKBA 2014
- Fundamental
- Price
- ECX $1.75
- AKBA $1.58
- Analyst Decision
- ECX Strong Buy
- AKBA Strong Buy
- Analyst Count
- ECX 1
- AKBA 6
- Target Price
- ECX $3.20
- AKBA $6.25
- AVG Volume (30 Days)
- ECX 8.1M
- AKBA 6.7M
- Earning Date
- ECX 11-03-2025
- AKBA 11-10-2025
- Dividend Yield
- ECX N/A
- AKBA N/A
- EPS Growth
- ECX N/A
- AKBA N/A
- EPS
- ECX N/A
- AKBA N/A
- Revenue
- ECX $822,663,229.00
- AKBA $225,071,000.00
- Revenue This Year
- ECX $817.95
- AKBA $53.38
- Revenue Next Year
- ECX $29.45
- AKBA $30.53
- P/E Ratio
- ECX N/A
- AKBA N/A
- Revenue Growth
- ECX 6.99
- AKBA 32.49
- 52 Week Low
- ECX $0.76
- AKBA $1.49
- 52 Week High
- ECX $3.25
- AKBA $4.08
- Technical
- Relative Strength Index (RSI)
- ECX 41.18
- AKBA 30.93
- Support Level
- ECX $1.68
- AKBA $1.49
- Resistance Level
- ECX $1.83
- AKBA $1.84
- Average True Range (ATR)
- ECX 0.27
- AKBA 0.12
- MACD
- ECX -0.06
- AKBA -0.00
- Stochastic Oscillator
- ECX 10.09
- AKBA 14.52
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.